ArticleScientific reports2019
Easy-to-use clinical tool for survival estimation in Ewing sarcoma at diagnosis and after surgery.
Article in Scientific reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07695311 (Precision Analysis of Fusion Genes in Ewing Sarcoma), which is not on this map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Precision Analysis of Fusion Genes in Ewing Sarcoma (ES) and Desmoplastic Small Round Cell Tumor (DSRCT), Then EWSR1 (Ewing Sarcoma Gene Breakpoint Region 1 Gene) Immunotherapy Without or With Anti-CTLA-4 (Botensilimab) and Anti-PD1 (Balstilimab)
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Clinical practice guidelines for the treatment of Ewing sarcoma (Spanish Sarcoma Research Group-GEIS).Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025Guideline
- Analysis of Migration and Invasion in Ewing Sarcoma.Methods in molecular biology (Clifton, N.J.) · 2027Article
- 18 F-FDG PET/CT Derived Volumetric Parameters Can Predict Outcome in Pediatric Ewing Sarcoma.Annals of nuclear medicine · 2026Article
- First case description of a highly aggressive thoracopulmonary primitive neuroectodermal tumor in a Moroccan adult male.Annals of medicine and surgery (2012) · 2026Article
- Potential biomarkers of Ewing sarcoma identified through a Europe-wide analysis of prospectively collected samples.Scientific reports · 2026Article
- Prognostic Modeling for Bone Sarcomas Based on a Large Prospective Cohort From a Tertiary Care Cancer Center in India.JCO global oncology · 2025Article
- Article
- Neutrophil to lymphocyte ratio (NTLR) predicts local control and overall survival after stereotactic body radiotherapy (SBRT) in metastatic sarcoma.Scientific reports · 2023Article
- Article
- Development and validation of a prognostic score at baseline diagnosis for Ewing sarcoma family of tumors: a retrospective single institution analysis of 860 patients.American journal of translational research · 2022Article
- A SEER-based nomogram accurately predicts prognosis in Ewing's sarcoma.Scientific reports · 2021Article
- [European radiology · 2021Article
- Biology and technology in the surgical treatment of malignant bone tumours in children and adolescents, with a special note on the very young.Journal of children's orthopaedics · 2021Article
- Number of metastases and their response to chemotherapy impact survival of patients with isolated lung metastases from bone-derived sarcoma.BMC cancer · 2021Article
- Assessment of treatment responses in children and adolescents with Ewing sarcoma with metabolic tumor parameters derived fromEuropean journal of nuclear medicine and molecular imaging · 2020Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Accurate survival estimations in Ewing sarcoma are necessary to develop risk- and response adaptive treatment strategies allowing for early decision-making. We aim to develop an easy-to-use survival estimation tool from diagnosis and surgery. A retrospective study of 1314 Ewing sarcoma patients was performed. Associations between prognostic variables at diagnosis/surgery and overall survival (OS), were investigated using Kaplan-Meier and multivariate Cox models. Predictive accuracy was evaluated by cross-validation and Harrell C-statistics. Median follow-up was 7.9 years (95%CI 7.6-8.3). Independent prognostic factors at diagnosis were age, volume, primary tumor localization and disease extent. 5 risk categories (A-E) were identified with 5-year OS of 88% (86-94), 69% (64-74), 57% (50-64), 51% (42-60) and 28% (22-34) respectively. Harrell C-statistic was 0.70. Independent prognostic factors from surgery were age, volume, disease extent and histological response. In categories A-B, 5y OS increased to 92% (87-97) and 79% (71-87) respectively for 100% necrosis and decreased to 76% (67-85) and 62% (55-69) respectively for <100% necrosis. In categories C-E, 5y OS increased to 65% (55-75), 65% (52-78) and 52% (38-66) respectively for ≥90% necrosis and decreased to 38% (22-54), 11% (0-26) and 7% (0-19) respectively for <90% necrosis. We present an easy-to-use survival estimation tool from diagnosis in Ewing sarcoma based on age, volume, primary tumor localization and disease extent. Histological response is a strong additional prognostic factor for OS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.